Sort by
Items per page

Send to

Choose Destination

Best matches for vaccine safety side effects:

Safety of vaccines used for routine immunization of U.S. children: a systematic review. Maglione MA et al. Pediatrics. (2014)

DNA Vaccines: Regulatory Considerations and Safety Aspects. Myhr AI et al. Curr Issues Mol Biol. (2017)

Nonclinical Safety Testing of RNA Vaccines. Hager G et al. Methods Mol Biol. (2017)

Search results

Items: 1 to 20 of 8522


Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.

Santos EMD, Noronha TG, Alves IS, Cruz RLS, Ferroco CLV, Brum RC, Oliveira PMN, Siqueira MM, Lima MC, Ramos FLP, Bragagnolo CM, Camacho LAB, Maia MLS.

Mem Inst Oswaldo Cruz. 2019 Mar 7;114:e180517. doi: 10.1590/0074-02760180517.


Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.

Huang LM, Chiu CH, Chiu NC, Lin CY, Li MT, Kuo TY, Weng YJ, Hsieh EF, Tai IC.

Vaccine. 2019 Mar 22;37(13):1827-1835. doi: 10.1016/j.vaccine.2019.02.023. Epub 2019 Feb 22.


Association between seasonal influenza vaccination with pre- and postnatal outcomes.

Getahun D, Fassett MJ, Peltier MR, Takhar HS, Shaw SF, Im TM, Chiu VY, Jacobsen SJ.

Vaccine. 2019 Mar 22;37(13):1785-1791. doi: 10.1016/j.vaccine.2019.02.019. Epub 2019 Feb 21.


Hypoallergenic Proteins for the Treatment of Food Allergy.

Yang L, Kulis M.

Curr Allergy Asthma Rep. 2019 Feb 22;19(2):15. doi: 10.1007/s11882-019-0846-6. Review.


The Efficacy and Safety of Intralesional Immunotherapy with Measles, Mumps, Rubella Virus Vaccine for the Treatment of Common Warts in Adults.

Chauhan PS, Mahajan VK, Mehta KS, Rawat R, Sharma V.

Indian Dermatol Online J. 2019 Jan-Feb;10(1):19-26. doi: 10.4103/idoj.IDOJ_142_18.


Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves.

Boumart Z, Daouam S, Bamouh Z, Jazouli M, Tadlaoui KO, Dungu B, Bettinger G, Watts DM, Elharrak M.

Vaccine. 2019 Mar 14;37(12):1642-1650. doi: 10.1016/j.vaccine.2019.01.067. Epub 2019 Feb 14.


Nanostructured cochleates: A multi-layered platform for cellular transportation of therapeutics.

Shende P, Khair R, Gaud RS.

Drug Dev Ind Pharm. 2019 Feb 15:1-37. doi: 10.1080/03639045.2019.1583757. [Epub ahead of print]


Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine.

Foerster J, Molęda A.

Vaccines (Basel). 2019 Feb 12;7(1). pii: E20. doi: 10.3390/vaccines7010020. Review.


[Vaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis].

Alves JM, Marques IB, Gil-Gouveia R.

Acta Med Port. 2019 Feb 1;32(1):81-85. doi: 10.20344/amp.9809. Epub 2019 Feb 1. Portuguese.


Serum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant in horses.

Nolan MB, Schulman ML, Botha AE, Human AM, Roth R, Crampton MC, Bertschinger HJ.

Vaccine. 2019 Feb 28;37(10):1299-1306. doi: 10.1016/j.vaccine.2019.01.053. Epub 2019 Feb 4.


Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.

Hong SS, Choi UY, Ma SH, Lee SY, Han SB, Kim KH, Kang JH, Kim JH.

Medicine (Baltimore). 2019 Feb;98(6):e14364. doi: 10.1097/MD.0000000000014364.


Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.

Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV.

MMWR Morb Mortal Wkly Rep. 2019 Feb 1;68(4):91-94. doi: 10.15585/mmwr.mm6804a4.


[Determination of tracheal cytotoxin in pertussis and diphtheria tetanus acellular pertussis vaccines using liquid chromatography-tandem mass spectrometry].

Long Z, Wei C, Guo Z, Ma X, Li Y, Yao J, Ji F, Li C, Huang T.

Se Pu. 2019 Feb 8;37(2):155-161. doi: 10.3724/SP.J.1123.2018.08006. Chinese.


Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study.

Ohfuji S, Ito K, Inoue M, Ishibashi M, Kumashiro H, Hirota Y, Kayano E, Ota N.

BMC Infect Dis. 2019 Jan 28;19(1):95. doi: 10.1186/s12879-019-3719-7.


Antiviral drugs for treatment and prophylaxis of seasonal influenza.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;61(1563):1-4. No abstract available.


A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer.

Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B.

Drug Des Devel Ther. 2019 Jan 14;13:309-316. doi: 10.2147/DDDT.S188925. eCollection 2019. Review.


Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

JAMA Oncol. 2019 Jan 24. doi: 10.1001/jamaoncol.2018.6258. [Epub ahead of print]


Questions and Concerns About HPV Vaccine: A Communication Experiment.

Shah PD, Calo WA, Gilkey MB, Boynton MH, Alton Dailey S, Todd KG, Robichaud MO, Margolis MA, Brewer NT.

Pediatrics. 2019 Feb;143(2). pii: e20181872. doi: 10.1542/peds.2018-1872. Epub 2019 Jan 22.


Enhanced passive surveillance of influenza vaccination in England, 2016-2017 - an observational study using an adverse events reporting card.

de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, Yonova I, Schuind A, Dos Santos G.

Hum Vaccin Immunother. 2019 Jan 16. doi: 10.1080/21645515.2019.1565258. [Epub ahead of print]


Supplemental Content

Loading ...
Support Center